The European Medicines Agency has recommended that 14 new products be approved in the EU, including Talvey (talquetamab), Janssen’s treatment for relapsed and refractory multiple myeloma (RRMM), which is now set to become the first therapy targeting GPRC5D.*
Talvey is for use as monotherapy in adult patients with RRMM who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?